scholarly journals The increased expression and aberrant methylation of SHC1 in non–small cell lung cancer: Integrative analysis of clinical and bioinformatics databases

2021 ◽  
Author(s):  
Yicheng Liang ◽  
Yangyang Lei ◽  
Minjun Du ◽  
Mei Liang ◽  
Zixu Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Integrative Analysis ◽  
Aberrant Methylation ◽  
Small Cell Lung ◽  
Bioinformatics Databases

scholarly journals Aberrant methylation modifications reflect specific drug responses in small cell lung cancer

Genomics ◽  
2021 ◽  
Vol 113 (3) ◽  
pp. 1114-1126
Author(s):  
Peixin Chen ◽  
Haoyue Guo ◽  
Yu Liu ◽  
Bin Chen ◽  
Sha Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Specific Drug ◽  
Small Cell Lung ◽  
Drug Responses

Aberrant methylation of FBN2 in human non-small cell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 50 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Hong Chen ◽  
Makoto Suzuki ◽  
Yohko Nakamura ◽  
Miki Ohira ◽  
Soichiro Ando ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

scholarly journals Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer

2016 ◽  
Vol 23 (4) ◽  
pp. 90-97 ◽  
Author(s):  
C Yang ◽  
C Sun ◽  
X Liang ◽  
S Xie ◽  
J Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mrna Expression ◽  
Cell Lung Cancer ◽  
Expression Profiles ◽  
Small Cell ◽  
Integrative Analysis ◽  
Small Cell Lung

scholarly journals Aberrant methylation ofTMS1 in small cell, non small cell lung cancer and breast cancer

2003 ◽  
Vol 106 (2) ◽  
pp. 198-204 ◽  
Author(s):  
Arvind Virmani ◽  
Asha Rathi ◽  
Kenji Sugio ◽  
Ubaradka G. Sathyanarayana ◽  
Shinichi Toyooka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

scholarly journals Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1523
Author(s):  
Federico Pio Fabrizio ◽  
Angelo Sparaneo ◽  
Andrea Fontana ◽  
Tommaso Mazza ◽  
Paolo Graziano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Epigenetic Mechanism ◽  
Aberrant Methylation ◽  
Small Cell Lung

The silencing of SPARC (secreted protein acid and rich in cysteine) gene through methylation of its promoter region represents a common event in many solid tumors and it is frequently associated with tumor progression and an aggressive clinical outcome. Anyhow, the data concerning the epigenetic mechanism of SPARC deregulation and its prognostic value in lung cancer are still incomplete. We explored the aberrant methylation of SPARC and its effects in 4 non-small cell lung cancer (NSCLC) cell lines and 59 NSCLC tissues and correlated the methylation levels with clinical-pathological features and disease outcome of patients. In 3 out of 4 tumor cell lines high SPARC methylation levels were observed. An inverse correlation between the epigenetic silencing and SPARC expression was confirmed by 5-Aza-2′-deoxycytidine ((5-Aza-CdR) treatment that also significantly induced a reduction in cell viability, proliferation and tumor cell migration. In tissues, the DNA methylation levels of the SPARC gene were significantly lower in paired non-neoplastic lungs (NLs) and normal lungs distant from tumor (NLDTs) than in NSCLCs (p = 0.002 and p = 0.0034 respectively). A promoter hypermethylation was detected in 68% of squamous cell carcinoma (SqCCs, 17/25) and 56% of adenocarcinoma (ADCs, 19/34), with SqCC showing the highest levels of methylation. Higher SPARC methylation levels were significantly associated with higher mortality risk both in all NSCLCs early stage patients (Hazard Ratio, HR = 1.97; 95% Confidence Interval, CI: 1.32–2.93; p = 0.001) and in those with SqCC (HR = 2.96; 95% CI: 1.43–6.12; p = 0.003). Promoter methylation of SPARC gene should represent an interesting prognostic biomarker in NSCLC, with potential application in the squamous early-stage context. Further research in this setting on larger independent cohorts of lung patients with different histologies and stages of disease are warranted.

Aberrant methylation of ADAMTS1 in non-small cell lung cancer

2008 ◽  
Vol 187 (2) ◽  
pp. 80-84 ◽  
Author(s):  
Jin Eun Choi ◽  
Dong Sun Kim ◽  
Eun Jin Kim ◽  
Myung Hwa Chae ◽  
Sung Ick Cha ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

scholarly journals Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer

2013 ◽  
Vol 29 (4) ◽  
pp. 1308-1314 ◽  
Author(s):  
MAKOTO SUZUKI ◽  
KENJI SHIRAISHI ◽  
AYAMI EGUCHI ◽  
KOEI IKEDA ◽  
TAKESHI MORI ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer

2014 ◽  
Vol 20 (17) ◽  
pp. 4660-4672 ◽  
Author(s):  
Satoshi Noguchi ◽  
Akira Saito ◽  
Masafumi Horie ◽  
Yu Mikami ◽  
Hiroshi I. Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Integrative Analysis ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document